Tay-Sachs disease is an autosomal recessive disorder caused by a deficiency of the lysosomal enzyme, P-N-acetylhexosaminidase A, a heteropolymer composed of two polypeptides called a and 13 (1, 2) . In this disorder, mutations in the a-chain gene render the enzyme defective, resulting in the accumulation of GM2 monosialoganglioside in the nervous system. Tay-Sachs disease is really a group of disorders, ranging in clinical severity from mild to fatal (1) (2) (3) and differing in biochemical parameters, including (i) residual enzyme activity (4), (ii) immunoprecipitable a-chain polypeptide (5) , and (iii) detectable a-chain mRNA (6, 7) . Such variations reflect the consequences of different a-chain genetic lesions. Although the disease is rare, Jews of Eastern European descent, Ashkenazi Jews, have a 10-fold higher gene frequency than does the general population for a severe form of the disorder known as classic Tay-Sachs disease. In contrast to the heterogeneity described above, Ashkenazi Jews with classic Tay-Sachs disease have one clinical course leading to death in early childhood and identical biochemical profiles-i.e., lack of residual enzyme activity, absence of immunoprecipitable a-chain polypeptide, and inability to detect a-chain mRNA (1, (8) (9) (10) . Southern blot analysis of genomic DNA from Ashkenazi patients revealed an intact gene (11) that was transcriptionally active (12) . It has been assumed that only one mutation gives rise to the severe form of Tay-Sachs disease in this ethnic group (1) .
This report describes the isolation of the a-chain gene from an Ashkenazi Jewish patient with classic Tay-Sachs disease and the identification of a mutation in a splicejunction within that Assay for a-Chain Mutation. DNA for analysis was isolated from cultured fibroblasts (20) or whole-blood leukocytes (24) . Two 23-base oligonucleotides (PCA1 and PCA2) complementary to sequences flanking the a-chain mutation were used as primers in the polymerase chain reaction (PCR) (25) to amplify a 135-bp sequence of genomic DNA encompassing the mutation (Fig. 1A ). Genomic DNA (1 ,ug) served as the initial template for primers PCA1 and PCA2, which were present in the 100-,ul reaction mixture at a concentration of 100 mM. The chain reaction was carried out by using the Klenow fragment of DNA polymerase I as described (25) . After 22 cycles ofreplication, halfofthe reaction mixture was incubated with Dde I overnight at 37°C. After extraction with phenol/chloroform, 1:1 (vol/vol), the reaction products were precipitated with ethanol, applied to an 8% polyacrylamide (19:1 methylenebisacrylamide) gel and electrophoresed in a Tris acetate/EDTA buffer, pH 8.0, at constant voltage until the bromophenol blue dye reached the bottom of the gel. Samples were transferred electrophoretically in the same buffer from the gel to a nylon membrane (Nytran, 0.2 ,um) at a constant amperage of (200 mA) overnight at 4°C. DNA was denatured by soaking the membrane in 1 M NaCl/0.5 M NaOH for 30 min. After neutralization in 0.5 M Tris, pH 7.4/1.5 M NaCl, the membrane was baked for 1 hr at 60°C to bind the DNA. Membrane-bound DNA was hybridized (manufacturers conditions) at 65°C to a 32P-labeled 41-base oligonucleotide specific for a section of exon 12 (Fig. 1B) . Membranes were washed as described by the manufacturer and exposed to x-ray film in the presence of a Cronex Hi Plus intensifying screen (DuPont).
In an alternate assay the polymerase chain reaction was carried out by using Taq I polymerase as described by the manufacturer. Without prior digestion with Dde I, duplicate sets of samples (7-,ul aliquots) were applied, denatured, and fixed to Biotrans membranes (0.2 um) according to the DNA dot-blot protocol described by the manufacturer. Both sets of samples were prehybridized for 1 
, and the other set was hybridized with a 19-base oligomer complementary to the sense strand of the mutant allele ( 12 and has the sequence 5' G-G-G-G-A-G-A-A-T-A-T-G- 
RESULTS AND DISCUSSION
Identification of the a-Chain Mutation. Southern analysis has shown (11) that the restriction enzyme cleavage patterns of the a-chain gene of Ashkenazi Jewish patients with classic Tay-Sachs disease were identical to those observed in normal controls, indicating that the genetic lesion was either a small deletion or a single-base-pair change. a-Chain mRNA was lacking in mRNA preparations from cultures of classic Tay-Sachs patients from this ethnic group, suggesting faulty transcription or incorrect RNA processing that had resulted in an unstable a-chain message (6). These observations prompted the search for a single-base-pair change or small deletion by sequence analysis of the promoter region, splice junction regions, and polyadenylylation signal area of the a-chain gene. The first step in this study required isolation of the mutant a-chain gene harboring the mutation. Toward that end a genomic library was constructed in AEMBL3 with DNA obtained from fibroblasts of an Ashkenazi Jewish patient with classic Tay-Sachs disease (GM2968). The library contained 2 x 106 independent recombinant phage particles and was screened for the a-chain gene by using the a-chain cDNA, pBHa-5 (9) These sequences from GM2968 exactly matched those in corresponding areas of the normal a-chain gene (21) with the single exception of a cytidine residue that substituted for a guanosine as the first nucleotide at the 5' boundary of intron 12 (Figs. 1 and 2 ). In higher eukaryotes almost all intron sequences adhere to the "G-T/A-G rule" (26)-i.e., they begin at the 5' end with dinucleotide G-T and terminate with dinucleotide A-G at the 3' end. Substitutions at these invariant regions can result in mRNA splicing errors (27, 28) . The replacement of G-T at the 5' boundary of exon 12 with dinucleotide C-T is likely to cause aberrant splicing in the a-chain mutant gene. An unstable a-chain message is presumably produced, explaining our inability to detect this message in Ashkenazi Tay-Sachs patients.
Assay for the Splice Junction Mutation. Identification of a splice junction alteration in one patient allowed testing for its presence in other Ashkenazi patients and obligate heterozy- Tay-Sachs disease in the region surrounding the 5' boundary of exon 12. DNA sequence analysis was performed with plasmids containing exon 12 ofgenomic DNA from a normal subject (21) and from patient GM2968 as templates for the sequencing reaction. The primer used was an exon-12-specific oligomer with the sequence 5' G-T-A-C-C -C-C-T-G-A-G-C-A-G-A-A-G-G (Fig. 1A) . In practice only the 120-bp fragment in the normal and the 85-bp fragment in the mutant is observed because the 41-base 32P-labeled probe utilized in Southern analysis ofthe samples does not hybridize to the 35-bp fiagment (Fig. 1B) . The alternate assay using allele-specific probes is rapid and, therefore, useful for screening large numbers of heterozygote carriers.
Analysis of Patients and Heterozygote Carriers and Noncarriers for Splice Junction Mutation. As expected, the DNA isolated from two normal subjects, an Ashkenazi Jew (D.B.) and a non-Jewish donor (IMR90), was negative for the splice junction mutation (Fig. 3A) . DNA from a non-Jewish French Canadian patient with classic Tay-Sachs disease (WG107) in which 7.6 kilobases at the 5' end of the a-chain gene are missing (19) gave a similar result (Fig. 3A) . Assuming that one mutation gives rise to the classic form of Tay-Sachs disease and knowing that this disease is inherited in an autosomal recessive manner (i.e., both alleles must be mutated for expression of the disorder), I expected DNA from GM2968 and GM515, two cell strains of Ashkenazi patients with classic Tay-Sachs, to be homozygous for the splice junction mutation. However, GM2968, the cell strain originally used to clone the mutant a chain, had only one allele with the splice . The schematic below A shows the genotypes of GM2968 (affected child), GM3052 (mother), and GM3051 (father). The shaded areas signify the normal a-chain allele. S, splice-junction mutation; 0, another mutation.
Proc. Natl. Acad. Sci. USA 85 (1988) junction mutation, and GM515 lacked the mutation (Fig. 3A) .
The simplest explanation for these results is that at least two mutations rather than a single mutation underlie the classic form of Tay-Sachs disease in the Ashkenazi group. GM515 must bear a different a-chain mutation in both alleles, whereas GM2968 bears one allele with the splice junction mutation; the second allele harbors a different mutation.
Since the splice junction assay is specific for only that mutation, GM515 appears to have a normal genotype and GM2968 appears to have that of a heterozygote carrier, but both must carry two defective a-chain alleles. Since GM2968 must inherit the splice junction mutation from one parent and another mutant allele from the second parent, it would be anticipated that only one parent would carry the splice junction mutation. In fact, the genotypes of the parents are consistent with this prediction. GM3051, the father of GM2968, has one allele with the splice junction mutation, whereas GM3052, the mother, does not (Fig. 3A) . GM3052 must carry a different mutation not detected by our assay. Fig. 3B demonstrates another family in which the affected child (R.S.) and the mother (Z.S.) exhibit the splice junction mutation, each in one allele; therefore, the father (M.S.) must carry a different mutation. In a third family (Fig.  3C) , neither parent carried the splice junction mutation (B.B. and T.B.). Consistent with these findings, the affected child (R.B.) was negative for the splice junction mutation.
In both affected patients and heterozygote carriers ( Fig. 3  A and B) the intensity of the band representing the allele bearing the splice junction mutation is less than that of the normal allele. Theoretically, the intensities should be equivalent because each allele contributes 50% ofthe a-chain gene. This may result from the fact that the band representing the mutant is 35 bp smaller than that of the normal and, therefore, is more easily washed off the nylon membrane in the steps preceding binding to the probe.
To obtain some measure of the frequency of this mutation and its presumed role as a causative agent for classic Tay-Sachs disease among Ashkenazi Jews, we screened DNA isolated from leukocytes of (i) 14 additional obligate heterozygotes and (ii) 20 Ashkenazi Jews identified via enzymatic assay to be noncarriers for Tay-Sachs disease.
None of the noncarriers tested showed the splice-junction alteration. Six of the 20 carriers tested to date exhibited the splice junction mutation, a frequency of 30%. The actual percentage is viewed as preliminary because many more carriers must be assayed to obtain a credible frequency. Assay for the splice junction mutation and assays that will be developed for the other mutation(s) as they became known will be of practical importance for carrier testing in instances in which the enzymatic assay currently used is inconclusive. The dot-blot assay described is rapid and useful for screening large numbers of samples.
This discussion has assumed that the splice junction mutation at the 5' boundary of intron 12 is a functionally significant defect resulting in aberrant a-chain mRNA and not merely a neutral polymorphism. Examples off-thalassemias resulting from nucleotide changes at the conserved splice site sequences argues against the latter possibility (28). Substitution of an adenosine for guanosine at the conserved 5' dinucleotide G-T in the first intron of the /3-globin gene (29) and in the second intron of the 3-globin gene (30) resulted in abnormal RNA splicing. In addition, mutagenic conversion of the conserved splice junction G-T sequence to A-T in the rabbit globin gene led to aberrant gene transcripts (31) .
On the other hand, exceptions to the G-T/A-G rule have been reported and argue for the possibility that the splice junction mutation observed in Ashkenazi Jewish Tay-Sachs patients and heterozygote carriers has no functional consequences. The genes for normal human prothrombin (32) and human adenine phosphoribosyltransferase (33) each contain one G-C rather than G-T donor splice site, and the gene encoding the largest subunit of mouse RNA polymerase II contains two G-C donor splice sites (34) . However, ifthe G-T SC-T change we observe were a neutral polymorphism one would have expected to find it in the Ashkenazi noncarriers, unless the alteration arose on a background of the classical Tay-Sachs mutation and is tightly linked to it. All of the results presented in this study are consistent with this latter possibility. In that case, it would be erroneous to conclude that more than one mutation causes the classic form of Tay-Sachs disease in Ashkenazi Jews from the results ofthis study. Conclusive data are not available to distinguish between the possible interpretations of the data. Development of an assay for the functional effects of the a-chain splice junction mutation found in Ashkenazi Tay-Sachs patients is necessary to firmly establish its significance. 
